NEW YORK (GenomeWeb News) – 23andMe today announced the expansion of its online study conducted with Genentech for the biotech firm's oncology drug Avastin (bevacizumab).

In a post on 23andMe's blog, the Mountain View, Calif.-based company said that its study with Genentech, called InVite, is now open to any patient in the US who used Avastin before 2013 for treatment of metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, relapsed glioblastoma, metastatic renal cell carcinoma, or metastatic breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcripts, and more.

While James Watson and Francis Crick are credited for discovering the structure of DNA, Rich proved their theory of a double helix structure was correct when he produced a distinct image of the structure.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

According to MIT Technology Review, Apple is collaborating with researchers to develop apps for consumer DNA testing.